By Iain Gilbert
Date: Monday 25 Jun 2018
LONDON (ShareCast) - (Sharecast News) - AIM-listed functional food developer Provexis has secured a listing with high street health and wellbeing retailer Holland and Barrett for its Fruitflow dietary supplement product.
Fruitflow+ Omega-3, Provexis' two-in-one supplement, which supports healthy blood flow and normal heart function, will be listed in more than 660 Holland and Barrett stores across the UK and Ireland, together with Holland & Barrett Online, giving the supplement product widespread consumer exposure.
Holland and Barrett staff will be trained to understand and communicate the benefits of Fruitflow+ Omega-3 to prospective customers ahead of its launch in-store and online in August.
In June 2017, the Company secured a listing for the product with Amazon.co.uk.
Dawson Buck, chairman of Provexis, said, "The listing will help raise awareness of the proven benefits of Fruitflow across a substantial consumer audience, and the company's expanding Fruitflow+ dietary supplement business is expected to provide the company with an additional long-term income and profit stream."
"We look forward to working with Holland and Barrett to maximise recommendation, trial and repeat purchase of the product," added Buck.
As of 1020 BST, Provexis shares had shot up 16.25% to 0.46p.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 0.45p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 0.70 |
52 Week Low | 0.44 |
Volume | 1,290,949 |
Shares Issued | 2,345.89m |
Market Cap | £10.56m |
RiskGrade | 364 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:35 | 59,784 @ 0.45p |
16:35 | 59,784 @ 0.45p |
14:42 | 2,000 @ 0.51p |
14:40 | 398,800 @ 0.50p |
14:29 | 20,040 @ 0.50p |
You are here: research